Roberts Trading On AMEX

10 June 1997

Roberts Pharmaceutical started trading on the American Stock Exchangelast month under the symbol RPC. The company said that the move from the dealer-oriented, over-the-counter market to the public auction market of AMEX is expected to provide benefits to shareholders, such as a narrowing of the spread between bid and ask prices, reduced volatility, enhanced liquidity and greater visibility.

The company has launched two products from its own pipeline, Proamatine (midodrine HCL; Marketletter May 19) and Agrylin (anagrelide HCl; Marketletter March 24), and said it is "on a threshold of an exciting new phase in its growth cycle."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight